These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30073931)

  • 1. Protective Role of Silymarin in Early Doxorubicin-induced Cardiac Dysfunction in Children with Acute Lymphoblastic Leukemia.
    Hagag AA; El Shehaby WA; El-Abasy AI; Mabrouk MM
    Infect Disord Drug Targets; 2019; 19(2):133-140. PubMed ID: 30073931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective role of black seed oil in doxorubicin-induced cardiac toxicity in children with acute lymphoblastic leukemia.
    Hagag AA; Badraia IM; El-Shehaby WA; Mabrouk MM
    J Oncol Pharm Pract; 2020 Sep; 26(6):1397-1406. PubMed ID: 31964219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
    Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
    J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia.
    Krajinovic M; Elbared J; Drouin S; Bertout L; Rezgui A; Ansari M; Raboisson MJ; Lipshultz SE; Silverman LB; Sallan SE; Neuberg DS; Kutok JL; Laverdière C; Sinnett D; Andelfinger G
    Pharmacogenomics J; 2016 Nov; 16(6):530-535. PubMed ID: 26345518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404.
    Asselin BL; Devidas M; Chen L; Franco VI; Pullen J; Borowitz MJ; Hutchison RE; Ravindranath Y; Armenian SH; Camitta BM; Lipshultz SE
    J Clin Oncol; 2016 Mar; 34(8):854-62. PubMed ID: 26700126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.
    Lipshultz SE; Lipsitz SR; Mone SM; Goorin AM; Sallan SE; Sanders SP; Orav EJ; Gelber RD; Colan SD
    N Engl J Med; 1995 Jun; 332(26):1738-43. PubMed ID: 7760889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling cardiac mechanics in doxorubicin-induced cardiotoxicity following childhood acute lymphoblastic leukemia using a combination of cardiac magnetic resonance imaging, cardiopulmonary exercise testing and the CircAdapt model.
    Artz T; Caru M; Curnier D; Abasq M; Krajinovic M; Laverdière C; Sinnett D; Périé D
    J Biomech; 2023 Jun; 154():111616. PubMed ID: 37207545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omega 3 fatty acids can reduce early doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukemia.
    El Amrousy D; El-Afify D; Khedr R; Ibrahim AM
    Pediatr Blood Cancer; 2022 Jul; 69(7):e29496. PubMed ID: 34842343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of early anthracycline-induced cardiotoxicity in childhood cancer with dobutamine stress echocardiography.
    Lenk MK; Zeybek C; Okutan V; Ozcan O; Gökçay E
    Turk J Pediatr; 1998; 40(3):373-83. PubMed ID: 9763901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.
    Lipshultz SE; Miller TL; Scully RE; Lipsitz SR; Rifai N; Silverman LB; Colan SD; Neuberg DS; Dahlberg SE; Henkel JM; Asselin BL; Athale UH; Clavell LA; Laverdière C; Michon B; Schorin MA; Sallan SE
    J Clin Oncol; 2012 Apr; 30(10):1042-9. PubMed ID: 22370326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia.
    El-Shitany NA; Tolba OA; El-Shanshory MR; El-Hawary EE
    J Card Fail; 2012 Aug; 18(8):607-13. PubMed ID: 22858075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effect of taurine against doxorubicin-induced cardiotoxicity in rats: echocardiographical and histological findings.
    Barış VÖ; Gedikli E; Yersal N; Müftüoğlu S; Erdem A
    Amino Acids; 2019 Nov; 51(10-12):1649-1655. PubMed ID: 31673792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
    Lipshultz SE; Scully RE; Lipsitz SR; Sallan SE; Silverman LB; Miller TL; Barry EV; Asselin BL; Athale U; Clavell LA; Larsen E; Moghrabi A; Samson Y; Michon B; Schorin MA; Cohen HJ; Neuberg DS; Orav EJ; Colan SD
    Lancet Oncol; 2010 Oct; 11(10):950-61. PubMed ID: 20850381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia.
    Lipshultz SE; Lipsitz SR; Kutok JL; Miller TL; Colan SD; Neuberg DS; Stevenson KE; Fleming MD; Sallan SE; Franco VI; Henkel JM; Asselin BL; Athale UH; Clavell LA; Michon B; Laverdiere C; Larsen E; Kelly KM; Silverman LB
    Cancer; 2013 Oct; 119(19):3555-62. PubMed ID: 23861158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardioprotective effect of dexrazoxane during treatment with doxorubicin: a study using low-dose dobutamine stress echocardiography.
    Paiva MG; Petrilli AS; Moisés VA; Macedo CR; Tanaka C; Campos O
    Pediatr Blood Cancer; 2005 Dec; 45(7):902-8. PubMed ID: 16035077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spironolactone Attenuates Doxorubicin-induced Cardiotoxicity in Rats.
    Liu G; Liu Y; Wang R; Hou T; Chen C; Zheng S; Dong Z
    Cardiovasc Ther; 2016 Aug; 34(4):216-24. PubMed ID: 27097055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dexrazoxane Treatments Limits Subclinical Cardiac Dysfunction in Childhood Acute Lymphoblastic Leukemia Survivors Exposed to Doxorubicin Treatments.
    Lapointe MO; Caru M; Curnier D; Raboisson MJ; Andelfinger G; Krajinovic M; Laverdière C; Sinnett D; Périé D
    J Pediatr Hematol Oncol; 2023 Mar; 45(2):70-77. PubMed ID: 36161876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol.
    Lipshultz SE; Giantris AL; Lipsitz SR; Kimball Dalton V; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE; Colan SD
    J Clin Oncol; 2002 Mar; 20(6):1677-82. PubMed ID: 11896119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes.
    Lipshultz SE; Miller TL; Lipsitz SR; Neuberg DS; Dahlberg SE; Colan SD; Silverman LB; Henkel JM; Franco VI; Cushman LL; Asselin BL; Clavell LA; Athale U; Michon B; Laverdière C; Schorin MA; Larsen E; Usmani N; Sallan SE;
    Pediatrics; 2012 Dec; 130(6):1003-11. PubMed ID: 23166343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.
    Lipshultz SE; Lipsitz SR; Sallan SE; Dalton VM; Mone SM; Gelber RD; Colan SD
    J Clin Oncol; 2005 Apr; 23(12):2629-36. PubMed ID: 15837978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.